Grant name: Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
Funding organization: National Institutes of Health (NIH)
Total funding amount: Not applicable; access to biospecimens provided instead of direct funding.
Duration: Maximum project period is 5 years.
Primary objective: To provide access to biospecimens for tobacco-related research.
Key stakeholders: Researchers in tobacco control and public health.
Grant program context: Part of ongoing efforts to inform FDA's regulatory activities under the Family Smoking Prevention and Tobacco Control Act.
Funding source: NIH.
Significance: Addresses critical public health issues related to tobacco use.
Grant frequency: Recurring opportunity.
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits (with and without 501(c)(3) status)
For-Profit Organizations (including small businesses)
Local, State, County, and City Governments
Indian/Native American Tribal Governments (both recognized and unrecognized)
Federal Government Agencies
Other: Independent School Districts, Public Housing Authorities, Faith-based Organizations, Regional Organizations.
Non-domestic (non-U.S.) entities are not eligible to apply.
Non-domestic components of U.S. organizations are not eligible.
Studies must align with PATH Study objectives and tobacco regulatory science.
Exploratory or pilot studies are prioritized.
Applicants must contact the PATH Study team at least five months before submission to confirm biospecimen availability.
No direct funding is provided; access to biospecimens is granted instead.
Open Date: March 30, 2024
Application Due Dates: Various deadlines until October 30, 2026.
Applicants must comply with NIH Grants Policy Statement and other relevant regulations.
Applications must be submitted electronically via Grants.gov.
Compliance with the Research Instructions in the Application Guide is mandatory.
Applications must include a letter from the PATH Study team confirming biospecimen availability.
The PATH Study has been ongoing since 2011, with multiple waves of data collection.